This startup is taking a new approach to building celebrity brands. Read the pitch deck it used to raise $5M.
That's the general thesis that motivated CEO Chris Koch to found VO/D, which helps fund and operate celebrity-led ventures. With VO/D, Koch and his team wanted to flip the script: first build a product that can succeed on its own, then bring in celebrities or creators to help it reach the right audience.
"I think that was a big shift for the business that helped us differentiate as a studio model," Koch told Business Insider. He said the goal is to have talent serve as an "amplification tool" rather than the only thing drawing a consumer in.
VO/D started with freeze-dried candy before moving into the protein and supplements category, with new products to come next year. Koch said the company is looking to expand into more verticals. To that end, the company announced on Thursday a $5 million Series A funding round led by KarpReilly, a private-equity firm that has invested in brands like Koia, Salt and Straw ice cream, and Sprinkles cupcakes. Other investors included NFL players Saquon Barkley and Odell Beckham Jr.
"They really liked the portfolio approach of our studio," Koch said of the investors. "So being able to have exposure across multiple brands, and the success that we were having on our first portfolio brand, 1UP, was interesting to them, because they typically invest directly into individual brands."
VO/D launched in 2021 and received $2 million in financial backing in 2022 from a friends and family round. Investors in that round included the Tisch family, owners of the New York Giants. With that funding, VO/D invested in the candy industry, combining freeze-dried candy brand 1UP Candy with gaming YouTuber FaZe Rug.
"That was based on a consumer insight that we identified in novelty, experiential candy," Koch said. "You see it with Mountain Dew or Oreo in terms of innovation and collaborations, but you don't really see much of it in the candy aisle. And so we wanted to create new and interesting flavors and textures."
1UP Candy is in over 12,000 retailers across the US, and has grown revenue to over $10 million on a trailing 12-month basis.
VO/D's next three products will be Frosh, a protein-juice brand for kids; Joose, a fruity protein supplement; and Stealth, protein snacks for kids. VO/D hasn't yet announced the celebrities who are attached to those brands.
VO/D's deck opens with its logo.
The company shares a simple mission.
VO/D added that it had been backed by CPG PE Firm, KarpReilly, as it sought new investors.
KarpReilly has also invested in Spindrift, KeVita, Koia, and Sprinkles Cupcakes.
VO/D believes that the future of consumer brands will be owned and led by celebrities.
VO/D lists some of these celebrities, including Logan Paul. His brand Prime had $1.2 billion in revenue in 2023, though it has more recently faced struggles.
VO/D has developed its own approach to launching talent-led brands.
On the left, the slide has three categories: criteria, investment, and team. The left column, with white font, illustrates how VO/D tested these three areas, and on the right, in green, is the scale the company sees it growing to.
VO/D's process includes three steps. The first is 'identify.'
The slide says:
Identify category, insights, and innovation for a profitable consumer business.
Approach talent directly and initiate discussions.
Use proprietary tools to analyze talent, audience and market fit.
The last point includes criteria for how VO/D analyzes the talent. Some of the tools it uses include lifestyle interviews, reach breakdown, trending posts, and sentiment analysis.
The next step in the process is 'validate.'
VO/D has a "rigorous pre-launch process" that helps make sure the talent is fully engaged.
These steps include reviewing opportunities, negotiating market commitment, concept and creatives testing, and market testing.
The third step in the process is 'launch.'
The slide says, "Our trusted partner network ensures top-quality execution of the product vision."
VO/D provides a case study of one of its brands: 1UP Candy.
It highlights six things: consumer insight, talent fit, a launch partner, quick profitability, massive results, and major retail distribution.
VO/D shares its current initiatives and what is in the pipeline through 2026.
These include 1UP Candy, Joose, Frosh, and Stealth.
VO/D outlines a 'growth hack' through its 'storefront' FRI&NDS.
FRI&NDS is a live events platform that launched during the Super Bowl in New Orleans this year, hosting Odell Beckham Jr.'s party.
The final slide is for thanks and getting in touch with VO/D.
VO/D

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Business Insider
7 hours ago
- Business Insider
3 Quantum Computing Stocks with Positive Investor Sentiment – 7/28/2025
Quantum computing, though still in its early stages, is expected to be the next big revolution after artificial intelligence. This emerging technology can tackle complex problems more quickly than traditional computers due to its ability to process information using quantum bits (qubits) instead of regular bits. Thus, investing in quantum computing stocks could give long-term investors a chance to benefit from new technology and market growth. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. To find such stocks, take a look at TipRanks' Quantum Computing Stocks page. It allows you to compare stocks based on analyst consensus, price targets, and key technical indicators among others. When selecting stocks to buy, it can be helpful to consider the sentiments of other individual investors. With that in mind, here are today's top quantum computing stock picks, which have received a bullish investor sentiment signal based on several portfolios analyzed by TipRanks. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. IonQ (IONQ) – IonQ's advanced trapped-ion technology helps solve complex problems more efficiently than classical computers. It has raised over $1 billion to support its growth and aims to build systems with millions of qubits by 2030. Overall, the analyst consensus on the stock is Strong Buy. Also, the stock has a Positive investor sentiment signal. D-Wave Quantum (QBTS) – QBTS is known for its Advantage quantum computer, solving problems that classical supercomputers cannot. It is also advancing gate-based tech with fluxonium qubits, aiming for real-world impact and a 100,000-qubit scale. The stock has earned an analyst consensus of Strong Buy. Moreover, QBTS stock has a Positive investor sentiment signal. Rigetti Computing (RGTI) – RGTI disclosed a 36-qubit multichip system that achieved 99.5% two-qubit gate fidelity, cutting error rates in half compared to previous models. It plans to launch a 100+ qubit system by year-end, using a chiplet design that makes it easier to scale and improve performance. RGTI stock has an analyst consensus of Strong Buy and a Positive investor sentiment signal.


Business Insider
10 hours ago
- Business Insider
D-Wave Quantum initiated with a Buy at Rosenblatt
Rosenblatt initiated coverage of D-Wave Quantum (QBTS) with a Buy rating and $30 price target The firm believes D-Wave offers a differentiated way to gain exposure to the rapidly growing quantum computing market. Rosenblatt added that it believes quantum annealing, a subsector of quantum computing, offers advantages over both classical computing and gate-based quantum systems for optimization workloads. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.